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Although the mechanisms for sustained chemokine gradients and recurring cell inﬁltration in sterile peritonitis have not been
elucidated, toll-like receptors (TLRs) have been implicated. To abate the deleterious recruitment of neutrophils in sterile inﬂam-
mation, we repeatedly administered a TLR7 ligand that hyposensitized to TLR7 and receptors that converged on the MyD88-sig-
naling intermediary and reduced cellular inﬁltration in murine autoimmune models of multiple sclerosis and arthritis. To reduce
potential adverse eﬀects, a polyethylene glycol polymer was covalently attached to the parent compound (Tolerimod1). The proin-
ﬂammatory potency of Tolerimod1 was 10-fold less than the unconjugated TLR7 ligand, and Tolerimod1 reduced neutrophil rec-
ruitment in chemically induced peritonitis and colitis. The eﬀects of Tolerimod1 were mediated by the radioresistant cells in radia-
tion chimeric mice and by mast cells in reconstituted mast cell-deﬁcient mice (KitW-sh). Although the Tolerimod1 had weak proin-
ﬂammatory agonist activity, it eﬀectively reduced neutrophil recruitment in sterile peritoneal inﬂammation.
1.Introduction
The inﬂammatory response is a major host defense mecha-
nism to prevent infection or to repair injury [1]. However,
in the context of sterile inﬂammation the perpetual recruit-
ment of neutrophils into the local environment can lead to
deleterious sequelae from proteases and other products re-
leased from their granules [2]. The early events of inﬂamma-
tion include increased vascular permeability and enhanced
immune cell mobility to allow cells and proteins to access the
site of inﬂammation [3]. Chronicity is established when sus-
tained levels of chemokines attract the inﬂux of neutrophils
and monocytes. Early disruption of this recurring cycle and
reduction of neutrophil recruitment could suppress subse-
quent inﬁltration of other types of immune cells and could
then prevent tissue damage [4].
The myeloid diﬀerentiation primary response gene 88-
(MyD88) signaling pathway has been implicated in perpet-
uating the inﬂammatory response in experimental perito-
nitis and colitis. This pathway is shared by the TLRs except
TLR3, which uses the MyD88-independent TIR-domain-
containing adapter-inducing interferon-β (TRIF) pathway
[5]. In a previous study, we demonstrated that chronic admi-
nistration of low doses of a synthetic TLR7 ligand (9-benzyl-
8-hydroxy-2-(2-methoxyethoxy) adenine; designated here
as 1V136) provided pharmacological suppression of the
MyD88-signaling pathway and subsequently reduced the
severity of inﬂammation in mouse models of autoimmunity
[6].
We have synthesized modiﬁcations of 1V136 to study the
eﬀectsonpotencyandalterthepharmacodynamicstoreduce
potential toxicities [7]. One compound that was modiﬁed
with a 6 unit PEG moiety had reduced ability to induce in-
ﬂammatory cytokines in vitro and in vivo and was designated
Tolerimod1 [7]. TLR-mediated signals can be ultimately
protective in models of acute intestinal inﬂammation and
consideredtobetherapeutictargets[8,9].HenceTolerimod1
was selected to test our hyposensitization strategy to limit
inﬂammatory recruitment in mouse models of peritonitis
and inﬂammatory bowel disease.2 Mediators of Inﬂammation
In the present study, the hyposensitization eﬀect of repe-
ateddosagewiththeparentcompound1V136wasconﬁrmed
in the murine acute dextran sodium sulfate (DSS)-colitis
model. The anti-inﬂammatory eﬀects of Tolerimod1 were
also tested in the DSS-colitis and thioglycolate (TG)-elicited
peritonitismodels.ThePEGylatedcompoundwasequivalent
to the parent compound in its ability to reduce peritoneal
inﬂammation and DSS-colitis. Radiation chimeras using
wild-type (WT) and Tlr7−/− mice indicated that this eﬀect
was mediated by the radioresistant cells in the recipient and
not by the transferred bone marrow cells. In addition mast
cell-deﬁcient mice (KitW-sh) were relatively refractory to the
therapeutic treatment. However, the treatment response was
recapitulated in mice that had been reconstituted with bone
marrow cells enriched for mast cells. These results implicate
m a s tc e l l sa sap ri m a rye ﬀector cell for Tolerimod1 activity in
vivo.
2.MaterialsandMethods
2.1. Animals. C57BL/6 (wild type, WT) and KitW-sh/HNihr-
JaeBsmJ mice were purchased from the Jackson Laboratories
(Bar Harbor, MA, USA). Tlr7−/− mice were a gift from
Dr. Akira (Osaka University, Japan) and backcrossed for 10
generations onto the C57BL/6 background at University of
California, San Diego (UCSD). Bone marrow chimeras were
generated by injecting 107 bone marrow cells intravenously
into whole-body irradiated (950cGy) recipient mice [6].
KitW-sh mice were engrafted with mast cells by intravenous
(i.v.) injection of 106 mast cells as previously described [10].
All animal experiments were approved by the UCSD Institu-
tional Animal Care and Use Committee.
2.2. Reagents. Dextran sodium sulfate (DSS) was purchased
from Sigma (St Louis, MO). Thioglycolate (TG) medium,
PBS, RPMI 1640 medium, and DMEM were purchased from
Invitrogen (Carlsbad, CA, USA). RPMI 1640 and DMEM
were supplemented with 10% FCS, 100U/mL penicillin,
and 100μg/mL streptomycin. 1V136 (unconjugated TLR7
ligand) and PEGylated TLR7 ligand (Tolerimod1, TMX-302,
describedasc ompound1bin[7])werepreparedinourlabo-
ratoryaspreviouslydescribed[7,11].1V136andTolerimod1
were dissolved in DMSO as a 100mM stock solution and
kept at −20◦C until use. Endotoxin levels in all reagents were
measured using Endosafe (Charles River laboratory, Wilm-
ington, MA, USA). Endotoxin levels of the compounds were
<0.05EU/μmol.
2.3. Compound Activity Tests. The RAW264.7 mouse mono-
cyte macrophage cell line was obtained from ATCC (Rock-
ville, MD, USA) and cultured in DMEM (Irvine Scientiﬁc,
Irvine, CA, USA) supplemented with 10% heat-inactivated
fetal bovine serum, 2mM L-glutamine, and 100U/mL peni-
cillin/100μg/mL streptomycin). Primary bone marrow-deri-
ved dendritic cells (BMDCs) were prepared from C57BL/6
mice as described [12]. The cells (1 × 106/mL) were incu-
batedwiththeindicatedcompoundfor18hoursat37◦C,5%
CO2, and culture supernatants were collected. IL-6, IL-10,
IL-1β,T N F α, and KC were measured from the supernatants
or sera by ELISA (BD Bioscience, or eBioscience, San Diego
CA, USA). Minimum detection levels of these factors ranged
f r o m5t o1 5p g / m L .
2.4. Induction of DSS-Colitis. WT mice were given 2%
(wt/vol) DSS dissolved in sterilized, distilled water ad libitum
for 7 days. Mice were injected subcutaneously (subcuta-
neously) with daily doses of 1V136 (150nmol), Tolerimod1
(200nmol)orvehicleondays0to7.Onday8,miceweresac-
riﬁced and disease activity index (DAI; the combined score
of weight loss and intestinal bleeding) was determined as
described previously [13].
2.5. Induction of TG-Induced Peritonitis. Mice were injected
s.c. with a single dose (day-1 or -3) or three daily doses of
1V136(150nmol)orTolerimod1(200nmol).Onday0,mice
were intraperitoneally (i.p.) injected with 2mL 4% TG med-
i u m .P e r i t o n e a le x u d a t e sw e r ec o l l e c t e da t3hwi t h3m Lc o l d
PBS. Total cell number was determined by counting with
a hematocytometer. Peritoneal cells were cyto-centrifuged
and stained with Wright-Giemsa to determine diﬀerential
leukocyte counts.
2.6. Histological Analysis. Colons were ﬁxed in buﬀered for-
malin and embedded in paraﬃn. Five μms e c t i o n sw e r ec u t
and stained with hematoxylin and eosin (H&E). The sec-
tions were stained for myeloperoxidase (MPO) using rabbit
anti-MPO antibody (Abcam, Cambridge, MA) and horse-
radish peroxidase-(HRP) conjugated anti-rabbit IgG (Jack-
son ImmunoResearch, West Grove, PA, USA) by the His-
tology and Immunohistochemistry Shared Resources at the
Moores UCSD Cancer Center.
2.7. Myeloperoxidase (MPO) Assay. MPO activity (kinetic
assay) was performed as previously described with minor
modiﬁcations [14]. Brieﬂy, colon tissues were homogenized
in 0.5% hexadecyltrimethyl-ammonium bromide (Sigma) in
50mM phosphate buﬀer, pH 6.0. The homogenate was son-
icated for 10 seconds, frozen and thawed 3 times, and then
centrifuged for 15 minutes. Protein concentration in the
supernatants was quantiﬁed by bicinchoninic acid assay
(Thermo Scientiﬁc Pierce). The supernatants were diluted
1:30inreactionbuﬀer (0.68mM O-dianisidine, 50mM po-
tassium phosphate buﬀer, pH 6.0, 29mM H2O2), and MPO
activity was measured as the absorbance at 460nm during
the ﬁrst 2 minutes, and expressed as OD per minute per mg
of protein.
2.8. Assessment of Vascular Permeability. Brieﬂy, mice were
intravenously injected with 200μL 0.625% Evans blue solu-
tion 10min before TG injection. After two hours peritoneal
lavage was performed using 2mL cold PBS, and absorbance
at 620nm was measured.
2.9. Statistical Analysis. The data are represented as means ±
standard errors of the mean (SEM). The Mann-Whitney test
was used to compare two groups, and one-way ANOVA with
Dunnett’s post hoc test was used for multiple comparisonsMediators of Inﬂammation 3
to a control group using Prism 4 (GraphPad Software, San
Diego, CA, USA).
3. Results
3.1. Repeated Treatment with a TLR7 Ligand-Reduced Disease
Severity in DSS-Colitis. We previously demonstrated that
the repeated administration of a TLR7 ligand ameliorated
joint inﬂammation in the K/BxN serum-transferred arthritis
model and reduced inﬂammatory cell inﬂux in the EAE
model [6]. To examine this eﬀect on sterile abdominal in-
ﬂammation, we tested this treatment regimen in the DSS-
colitis model. Mice were treated daily with 150nmol s.c.
1V136 (unconjugated TLR7 ligand) starting on day 0 until
the end of the experiment (Figure 1(a)). This was the lowest
s.c. dosage that was eﬀective when administered s.c. in the
K/BxN serum transferred arthritis model [6]. Mice treated
with daily 1V136 exhibited signiﬁcantly lower DAI (P =
0.005, Figure 1(b)) and less body weight loss (P = 0.005,
Figure 1(c)). Decreased disease severity was concordant with
decreased MPO activity in the colons of 1V136-treated mice
(Figure 1(d)). Histological examination showed fewer ulce-
rative lesions and less inﬂammatory cell inﬁltration in the
colons of 1V136-treated mice compared to vehicle-treated
mice (Figure 1(e)).
3.2. Tolerimod1 Reduced Neutrophil Recruitment in TG-Elici-
ted Peritonitis. In a previous study, we observed that a higher
dose (500nmol) of 1V136 administered intraperitoneally or
intranasally resulted in TLR7-dependent adverse eﬀects [10].
To limit these adverse eﬀects, we prepared several modiﬁed
forms of the parent compound and tested them in vitro and
in vivo for chemokine and cytokine release [7]. Amongst
these compounds, one containing a 6-unit PEG chain, was
a weakly active TLR7 agonist (Tolerimod1). Dose titration
studies are shown with a murine macrophage cell line,
RAW264.7 cells, and primary murine BMDCs stimulated
withTolerimod1and1V136forcytokinerelease.Tolerimod1
(EC50RAW = 4.8μMa n dE C 5 0 BMDC = 3.9μM) was 10
times less potent than 1V136 (EC50RAW = 0.37μMa n d
EC50BMDC = 0.3μM) (Figures 2(a) and 2(b)).
The unconjugated parent TLR7 ligand (1V136) reduced
MPO-positive cell inﬁltration in DSS-colitis (Figure 1(d)),
indicating that 1V136 treatments attenuated neutrophil
recruitment into the colon. To further examine the mech-
anism of Tolerimod1 eﬀects on neutrophil recruitment,
Tolerimod1 was used in the TG-elicited peritonitis model
(Figures 2(c) and 2(d)). Mice received three daily treatments
(days-3, -2, and -1), or a single treatment on day-1 or day-
3 of Tolerimod1, and peritonitis was induced on day 0.
Tolerimod1 treatment reduced overall cell inﬁltration
(Figure 2(c)), primarily neutrophil inﬂux (Figure 2(d)) into
the peritoneal cavity. In addition mice that were pretreated
with daily s.c. (200nmol) or oral (200nmol) Tolerimod1 for
three days and then were injected with TG intraperitoneally
had a signiﬁcant reduction in total neutrophil count after 3h
(2.33 ± 0.33 × 106∗,a n d2 .39 ± 0.38 × 106∗,r e s p e c t i v e l y ,
comparedto4.60±0.51×106 inthevehiclecontrol; ∗P<0.05
by one-way ANOVA). However, the number of inﬁltrating
monocytes after 3 days daily s.c. (200nmol) of pretreatment
was not signiﬁcantly reduced (2.43 ±0.30 ×106 versus 3.1 ±
0.5 ×106 in the vehicle control).
3.3. Reduction in Peritoneal Neutrophil Inﬂux Was Associated
with Reduced Local Chemokine Levels. The immune cell
recruitment is inﬂuenced by numerous factors, such as local
chemokine secretion and vascular permeability. Hence, we
examined the levels of chemokines and cytokines in sera
and peritoneal lavages 3h after TG peritonitis induction.
Tolerimod1 treatment signiﬁcantly reduced KC levels in
the lavage (Figure 3(a)), but IL-1β levels were not reduced
(Figure 3(b)). In contrast, serum levels of KC and IL-6 were
not inﬂuenced by Tolerimod1 treatments (Figures 3(c) and
3(d)). IL-1β,T N F α, and IL-10 in the sera and peritoneal
lavageandIL-6intheperitoneallavagewerebelowdetectable
levels (data not shown). Tolerimod1 treatment did not alter
the vascular permeability as measured by Evans blue dye
extravasation (Figure 3(e)).
3.4. Radioresistant Mast Cells Were Involved in Anti-Inﬂamm-
atory Eﬀects of Tolerimod1. Since Tolerimod1 treatment inf-
luences local chemokine levels, but not systemic levels of
chemokinesorcytokines,wethoughtitimportanttoidentify
the cell types in the local tissue involved in the eﬀects
of Tolerimod1. Tolerimod1 treatment in Tlr7−/− mice did
not reduce TG-elicited recruitment of inﬂammatory cells
(Figures 4(a) and 4(b)), indicating that the treatment eﬀects
of Tolerimod1 were TLR7 dependent. To further test the
involvement of hematopoietic cells in the eﬀects of Toleri-
mod1treatment,Tlr7−/− and WT (C57BL/6) radiation bone
marrowchimericmiceweregenerated.Interestingly,reduced
peritoneal neutrophil recruitment after TG injection was ob-
served in the WT donor → Tlr7−/− recipients, but not
in Tlr7−/− donor→WT recipients (Figures 4(c) and 4(d)),
suggesting that the radioresistant cell population was pre-
dominantly mediating the anti-inﬂammatory eﬀects of Tole-
rimod1.
Mast cells are relatively radioresistant and involved in
many inﬂammatory processes associated with an increase in
vascular permeability [15–17]. To examine the potential role
of mast cells, mast cell-deﬁcient KitW-sh mice were treated
with Tolerimod1 for 3 days, and peritonitis was induced.
Tolerimod1 treatment did not reduce neutrophil inﬁltration
into the peritoneum of KitW-sh mice (Figure 4(e)). Further-
more, the response to Tolerimod1 treatment in KitW-sh mice
was restored by reconstitution of WT mast cells into KitW-sh
mice (Figure 4(e)). Of note is the relative neutrophilia in
KitW-sh mice,whichappearedasatrendinthehigherneutro-
phil recruitment in the mast cell replete mice [18].
3.5. Tolerimod1 Reduced Severity of DSS-Colitis. Repeated
administration of unconjugated TLR7 ligand, 1V136, redu-
ced neutrophil inﬂammation in DSS-colitis (Figure 1). Our
data indicate that the inhibitory eﬀect of Tolerimod1 on
neutrophil inﬁltration was at least in part mediated by mast
cells, which are known to be involved in intestinal inﬂamma-
tion in DSS-colitis [19]. Hence, we treated DSS-colitis mice
with Tolerimod1 s.c. or orally with daily Tolerimod1 for4 Mediators of Inﬂammation
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Figure 1: TLR7 ligand hyposensitization reduces the inﬂammation of DSS-induced experimental colitis. (a) Experimental protocol of
induction of DSS-induced colitis and treatment regimen. WT mice (n = 5) received 2% DSS for 7 days. Mice were s.c. treated with 150nmol
1V136 or vehicle. (b) Disease activity index, (c) percent body weight changes, and (d) MPO activity of colonic tissue was determined as
described in Section 2. Data are expressed as means ± SEM and are representative of 2 independent experiments. ∗Denotes P<0.05 by
Mann-Whitney test. (d) Examples of colons of vehicle- or 1V136-treated colitis mice that were removed and prepared for histological
examination. Original magniﬁcation is ×100. Calibration bar: 100μm.Mediators of Inﬂammation 5
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Figure 2: PEGylated TLR7 ligand reduced neutrophil recruitment in TG-elicited peritonitis. RAW264.7 (a) and primary BMDC (b) were
treated 18h with Tolerimod1 (TLM1), and TNFα and IL-6 in the supernatants were measured by ELISA. (c and d) WT mice (n = 7t o1 0
per group) were treated daily for three days (-3, -2, and -1) or one day (-3 or -1 day) of s.c. 200nmol Tolerimod1 (TLM1). Peritonitis was
induced on day 0. Total cell number (c) and total neutrophil number (d) recovered in the peritoneal lavage were measured. Data shown are
mean ± SEM and are pooled 2 independent experiments that showed similar trends. ∗Denotes P<0.05 by one way ANOVA with Dunnett’s
post hoc testing compared to the vehicle-treated group.
aw e e k( Figure 1(a)). Both s.c. and oral administration of
Tolerimod1 reduced the DAI and prevented body weight
loss (Figures 5(a) and 5(b)). Histologic examination revealed
a reduction in inﬂammatory cell inﬁltration in the lamina
propria (Figure 5(c)). There was also a notable reduction in
staining for MPO-positive neutrophils (Figure 5(c)).
4. Discussion
Neutrophils are the ﬁrst responders in acute injury and in-
ﬂammation. During the early phase of inﬂammation, neu-
trophils migrate from blood vessels to the site of inﬂamma-
tion. In the tissue, neutrophils can then mediate damage by
releasing the contents of their granules and further amplify-
inginﬂammatoryprocesses[1].Wepreviouslydemonstrated
that repeated administration of an unconjugated TLR7
ligand (1V136) reduced joint inﬂammation in the neutro-
phil-dependent K/BxN serum transfer arthritis model [6]. In
the current study, we tested the anti-inﬂammatory eﬀects of
TLR7 ligands in the TG peritonitis and DSS-colitis models.
Neutrophil-associated inﬂammation was markedly attenu-
ated by oral or subcutaneous administration of doses of
the parent compound, 1V136, or a PEG-modiﬁed version,
Tolerimod1 [7]. Although proinﬂammatory potencies of
PEGylated TLR7 ligand (Tolerimod1) was 10 times less than
unconjugated TLR7 ligand, it retained anti-inﬂammatory
properties in DSS-colitis as well as TG-elicited peritonitis
models.
Mucosal administration of 1V136 resulted in hypother-
mia and caused anorexic behavior that was associated with
TNFα release [10]. Hence, we hypothesized that the adverse
eﬀects could be attenuated by reducing the proinﬂammatory6 Mediators of Inﬂammation
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Figure 3: Tolerimod1 treatment reduced local chemokine release but had no eﬀect onsystemic proinﬂammatorycytokine levels. TG-elicited
peritonitiswasinducedinTolerimod1(TLM1)orvehicle(veh)-treatedmice(n = 8–10pergroup).Seraandperitoneallavagewereharvested
3h after TG injection. Levels of KC (a) and IL-1β (b) in the lavage and KC (c) and IL-6 (d) in sera were measured by ELISA. IL-1β,T N F α,
and IL-10 in the sera or lavage, or IL-6 in the lavage, were below detection levels. (e) Vascular permeability was measured by Evans blue
assay. Peritoneal lavage was collected 2h after TG injection. Data shown are mean ± SEM and are pooled from 2 independent experiments
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NS indicates not signiﬁcant.
potency of the drug. Among the PEGylated derivatives of
1V136 that we prepared, we found that a conjugate with a
6-unit PEG chain (Tolerimod1 in this study) had minimal
TLR7-dependent proinﬂammatory activities [7, 11]. We,
therefore, selected this conjugate to study for anti-inﬂam-
matory applications. Tolerimod1 treatment reduced neutro-
phil inﬂammation in both DSS-induced colitis, despite our
initial concern that Tolerimod1 would not be able to retain
anti-inﬂammatorypropertiesduetoitslowagonisticactivity.
In the DSS-colitis model, treatment with TLR7 ligands
reduced MPO activity in the colon, indicating that the treat-
ment resulted in reduction of neutrophil recruitment. We,
therefore, used TG-elicited peritonitis, a widely used model
of sterile inﬂammation to measure the migratory function
of neutrophils [20–23], and to evaluate the treatment ef-
fectsofTolerimod1onneutrophilrecruitment.Althoughthis
model does not fully represent neutrophilic inﬂammation in
humans, it can provide mechanistic insights into this hypo-
sensitizationtreatment.Thecurrentstudydemonstratedthat
the beneﬁcial eﬀects of Tolerimod1 are TLR7 dependent. In
addition, the reduced acute neutrophil accumulation in the
peritoneal cavity was accompanied by a reduction in KC, a
potent neutrophil chemoattractant. These results suggested
that a weak TLR7 agonist could inﬂuence neutrophil-medi-
ated inﬂammation by reducing the chemokine recruitment
to the site of inﬂammation.
Although we studied sterile inﬂammation, clinical peri-
tonitis is usually associated with infections. However, humanMediators of Inﬂammation 7
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Figure 4:Radioresistantmastcells wereinvolved insuppressionofneutrophilrecruitmentbyTolerimod1treatment. (a)WT, (b) Tlr7−/−,o r
chimeric mice [WT→ Tlr7−/− (c), and Tlr7−/− →WT (d)] were treated with 200nmol Tolerimod1 (TLM1) s.c. for 3 days and peritonitis
was induced with TG (n = 4 to 8 per group). (e) Mast cell-deﬁcient Kit
W-sh mice or Kit
W-sh mice reconstituted with WT mast cells were
treated with 200nmol Tolerimod1 (TLM1) s.c. for 3 days, and peritonitis was induced with i.p. TG. The peritoneal cells were recovered by
lavage after 3 hours and quantitated. Data shown are mean ± SEM and are pooled from 2 independent experiments that showed similar
trends. P values are from comparisons of vehicle (veh)- and Tolerimod1-treated groups by Mann-Whitney test.
responses such as in dialysis-associated peritonitis are also in
part TLR mediated. A murine model that mimics the pro-
gressionofabacterialperitonitisbyinjectinglyophilizedcell-
free supernatant prepared from Staphylococcus epidermidis
(termed “SES”) has been developed [24]. TLR2 plays a pre-
dominant role in mediating the proinﬂammatory eﬀects of
S E So nh u m a nc e l l s[ 25] and soluble TLR2-attenuated in-
ﬂammation in the SES peritonitis model [26]. Although we
didnot formallytestthis model, wepreviouslydemonstrated
that TLR7 ligand administration does demonstrate “cross
tolerance” for TLR2 and does not reduce host defense in a
murine infectious disease model [6]. Hence it is possible that
interventionwithaweakTLR7agonistcouldprovebeneﬁcial
in other TLR-dependent models of peritonitis.
TheMyD88pathwayisinvolvedinchemokineexpression
in macrophage/dendritic cells [27], and chemokine receptor
expressiononneutrophils[28].Inmurinemodelsofmyocar-
dial injury and aseptic brain injury, neutrophil recruitment
to these sites was severely impaired in MyD88-deﬁcient mice
[28, 29]. Also, neutrophil mobility was shown to depend on
radiosensitivecellsinbonemarrowchimerasinthesemodels
of injury [28]. Independently, we reported that repeated
injection of an unconjugated TLR7 ligand (1V136) induced
refractoriness to subsequent activation of the MyD88 signal-
ing pathway and that radiosensitive hematopoietic cells were
involved in this process [6]. Hence, we thought that hema-
topoieticcellsalsocontributedintheTolerimod1eﬀects.Un-
expectedly, experiments reported here using radiation bone8 Mediators of Inﬂammation
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Figure 5: Tolerimod1 reduced the severity of DSS-induced colitis (a and b) DSS-colitis mice (n = 12 per group) were treated with 200nmol
Tolerimod1 subcutaneously (SC) or orally (PO) for 7 days. Disease activity index (a) and body weight loss (b) were evaluated. (c) The colons
isolated from mice treated s.c. with vehicle or Tolerimod1 were stained with hematoxylin or eosin, or immunostained for MPO. Data shown
are mean ± SEM and are pooled from 2 independent experiments that showed similar trends. ∗Denotes P<0.05 by one-way ANOVA with
Dunnett’s post hoc testing compared to the vehicle-treated group.
marrow chimeric mice, and mast cell-deﬁcient KitW-sh mice
showed that radioresistant cells and mast cells were involved
in the suppressive eﬀects of Tolerimod1. Although mast cells
are derived from bone marrow cells, they are relatively resis-
tant to radiation-induced cell death [30]. The anti-inﬂam-
matory eﬀects of Tolerimod1 were diminished in mast-def-
icient KitW-sh mice and were partially restored in KitW-sh
mice engrafted with WT mast cells, indicating that mast
cells played a signiﬁcant role in the reduction of neutrophil
recruitment in the TG peritonitis model.
Mast cells have also been suggested to play a proinﬂam-
matory role in models of colitis [31]. DSS-colitis was less
severe in mast cell-deﬁcient mice or rats [19, 32]. Interest-
ingly, mast cells and their mediators contributed in early vas-
cularpermeability seen in inﬂammation [33]and speciﬁcally
in TG-induced peritonitis [34]. Our results indicated thatMediators of Inﬂammation 9
there is no diﬀerence in vascular permeability, suggesting
that the treatment did not inﬂuence the release of mediators
involved in vascular permeability by mast cells.
TLR7expressionbyhostcellsisenhancedininﬂamedtis-
sues [35]. Therefore, a therapeutic strategy to target TLR7
wouldbemoredirectedtowardinﬂamed,ratherthannormal
tissues. In addition, tissue or mucosal mast cells also express
TLR7 [36, 37]. We demonstrated in this study that a weakly
potent TLR7 ligand could reduce severity of acute neutro-
philic inﬂammation in a mast cell-dependent manner. The
eﬀect did not involve radiosensitive immune cells, suggesting
that less immunosuppressive adverse eﬀects might occur.
Our ﬁndings indicated that Tolerimod1 treatment reduced
chemokine levels locally in the peritoneal lavage ﬂuid, but
not systemically. Tolerimod1 was orally active, reduced local
peritoneal, and colonic inﬂammation, without causing a sys-
temic inﬂammatory cytokine storm.
5. Conclusion
In conclusion, a PEGylated TLR7 ligand (Tolerimod1) ex-
hibited less proinﬂammatory potency than the parent com-
pound. Tolerimod1 reduced neutrophil inﬂammation in
murine models of experimental colitis and peritonitis. The
treatmenteﬀects of Tolerimod1 were mediated by radioresis-
tant cells, including mast cells. Tolerimod1 could be a new
candidate anti-inﬂammatory drug with potentially minimal
systemic adverse eﬀects.
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